Dialysis duel: does higher fluid volume or lower sodium improve patient outcomes?
NCT ID NCT07717255
First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time
Summary
This observational study looks at how different settings in haemodiafiltration (a type of dialysis) affect people with kidney failure. It compares high versus low fluid exchange volumes and two different sodium concentrations in the dialysis fluid. Researchers will track toxin removal, symptoms, cognitive function, nutrition, and fluid balance over a year to find the best approach.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help refine dialysis prescriptions to improve patient well-being and reduce complications.
- What could go wrong
- As an observational study, it cannot prove cause and effect. Results may not apply to all dialysis patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2025
- Expected to finish
-
Nov 2030
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult patients with ESKD receiving hemodialysis accross 5 dialysis units in East and North Hertfordshire NHS Trust , UK.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18 years or above. * Ability to give informed consent. * End stage kidney disease (ESKD) treated by haemodialysis for at least 3 months. * Prognosis \> 6 months as assessed by principal investigator (PI)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for End-stage kidney disease are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Lister Hospital, East and North Hertfordshire NHS Trust
RECRUITINGStevenage, Hertfordshire, SG1 4AB, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A tailored diet may lower heart risk in kidney failure
- Can digital tools and training help more kidney patients get transplants?
- Can almond, soy, or oat milk match dairy for nutrient absorption?
- Protein and saline mist may cut bleeding risk after tonsil removal
- Can a gene found in african ancestry explain kidney failure?
- Can lowering phosphate save hearts in kidney failure?